Johnson & Johnson's Fiscal Year is From January To December.
The item "Enterprise-Value-To-Ebitda-Ratio" stands at 11.63 as of 09/30/2025.
As of the end of Johnson & Johnson's third quarter, the item "Enterprise Value To Ebitda Ratio" stands at 11.63. This represents an increase of 5.64 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -23.03 percent compared to the value the year prior.
The 1 year change in percent is -23.03.
The 3 year change in percent is -1.99.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Enterprise Value To Ebitda Ratio | 905,699,262,464.00 |
![]() | AbbVie Inc - Enterprise Value To Ebitda Ratio | 399,570,305,024.00 |
![]() | Roche Holding AG - Enterprise Value To Ebitda Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Enterprise Value To Ebitda Ratio | 280,205,508,085.11 |
![]() | Novartis AG - Enterprise Value To Ebitda Ratio | 255,096,620,580.91 |